<DOC>
	<DOCNO>NCT02937701</DOCNO>
	<brief_summary>This trial design determine effect human body investigational medicine , ABP 710 , effect body investigational medicine give , comparable see licensed medicine , infliximab , patient moderate severe rheumatoid arthritis ( RA ) . This study assess investigational medicine safe effective treat moderate severe RA compare license medicine .</brief_summary>
	<brief_title>Study Assess ABP710 Safe &amp; Effective Treating Moderate Severe Rheumatoid Arthritis Compared Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subject ( man woman ) ≥ 18 ≤ 80 year old . Subject diagnose RA determine meeting 2010 American College Rheumatology ( ACR ) /European League Against Rheumatism classification criterion RA . Subject RA duration least 3 month . Subject active RA define ≥ 6 swollen joint ≥ 6 tender joint ( base 66/68 joint count exclude distal interphalangeal joint ) screen baseline least 1 follow screening : erythrocyte sedimentation rate ≥ 28 mm/hr serum Creactive protein &gt; 1.0 mg/dL Subject positive rheumatoid factor anticyclic citrullinated peptide screening . Subject take MTX ≥ 12 consecutive week stable dose oral subcutaneous MTX 7.5 25 mg/week ≥ 8 week receive investigational product willing remain stable dose throughout study . For subject nonsteroidal antiinflammatory drug low potency analgesic tramadol , Soma Compounds , Fioricet , Fiorinal , dose stable ≥ 2 week screen . For subject oral corticosteroid ( ≤ 10 mg prednisone equivalent ) , dose stable ≥ 4 week screen . Subject known history active tuberculosis . Subject negative test tuberculosis screening define either : negative purified protein derivative ( PPD ) define &lt; 5 mm induration 48 72 hour test place OR negative Quantiferon test Subject positive PPD history Bacillus CalmetteGuérin vaccination allow negative Quantiferon test . Subject positive PPD test ( without history Bacillus CalmetteGuérin vaccination ) subject positive indeterminate Quantiferon test allow follow : symptom tuberculosis accord worksheet provide sponsor , Amgen Inc. document history adequate prophylaxis initiation receive investigational product accordance local recommendation know exposure case active tuberculosis recent prophylaxis Subject history prosthetic native joint infection . Subject active infection history infection follow : active infection systemic antiinfectives use within 28 day first dose investigational product serious infection , define require hospitalization intravenous ( IV ) antiinfective ( ) within 8 week first dose investigational product recurrent chronic infection active infection , opinion investigator , might cause study detrimental subject Subject positive blood test human immunodeficiency virus . Subject positive hepatitis B surface antigen , hepatitis B core antibody , hepatitis C virus antibody result screen . Subject uncontrolled , clinically significant systemic disease diabetes mellitus , cardiovascular disease include moderate severe heart failure ( New York Heart Association Class III/IV ) , renal disease , liver disease , hypertension . Subject malignancy within 5 year EXCEPT treat consider cured cutaneous squamous basal cell carcinoma , situ cervical cancer , OR situ breast ductal carcinoma . Subject history neurologic symptom suggestive central peripheral nervous system demyelinate disease . Subject major chronic inflammatory disease connective tissue disease RA , exception secondary Sjögren 's syndrome . Subject concurrent medical condition , opinion investigator , could cause study detrimental subject . Subject laboratory abnormality screen , include follow : hemoglobin &lt; 9 g/dL platelet count &lt; 100 000/mm3 white blood cell count &lt; 3 000/mm3 aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x upper limit normal creatinine clearance &lt; 50 mL/min ( CockroftGault formula ) laboratory abnormality , , opinion investigator , prevent subject complete study interfere interpretation study result . Subject use commercially available investigational biologic therapy RA follow : anakinra , etanercept within 1 month first dose investigational product abatacept , tocilizumab , adalimumab , golimumab , certolizumab within 3 month first dose investigational product experimental commercially available biologic therapy RA within 3 month 5 halflives ( whichever longer ) first dose investigational product rituximab within 9 month investigational product along evidence incomplete B cell recovery Subject receive live vaccine within 28 day first dose investigational product plan receive live vaccine course study . Subject previously receive Remicade® ( infliximab ) biosimilar infliximab . Woman pregnant breast feeding , plan become pregnant enrol study 6 month last dose investigational product . Woman childbearing potential ( ie , neither surgically sterile postmenopausal ) agree use adequate contraception ( eg , true abstinence , sterilization , birth control pill , DepoProvera® [ medroxyprogesterone ] injection , contraceptive implant ) study 6 month last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>